https://www.onconius.com/blog-1 daily 1.0 2025-07-03 https://images.squarespace-cdn.com/content/v1/6411b07aaa32e618655cc0ee/cfd3bb89-868e-4ef1-a6b8-b54031f43244/Logo+negro+sog.png https://images.squarespace-cdn.com/content/v1/6411b07aaa32e618655cc0ee/b66f0505-2ed9-4854-9d23-08f9d8920292/Ipsen-master-logo-ACS-footer_320x90pix.png https://images.squarespace-cdn.com/content/v1/6411b07aaa32e618655cc0ee/e746fc70-f9e4-4c41-9270-03ee13c3f071/RRD-Logo2023-CMYK.jpg https://images.squarespace-cdn.com/content/v1/6411b07aaa32e618655cc0ee/b000c415-92d8-4467-a13d-3214890cda97/Novartis+Logo+RGB.png https://www.onconius.com/blog-1/comunicacin-mdico-paciente-clave-para-una-atencin-de-calidad monthly 0.5 2025-02-02 https://www.onconius.com/blog-1/controversias-en-cncer-renal monthly 0.5 2025-01-29 https://www.onconius.com/blog-1/la-importancia-del-ejercicio-fsico-en-el-paciente-oncolgico monthly 0.5 2024-07-20 https://www.onconius.com/blog-1/nivolumab-adyuvante-mejora-la-supervivencia-global-en-pacientes-con-cncer-de-vejiga-resultados-del-estudio-checkmate-274 monthly 0.5 2024-04-06 https://www.onconius.com/blog-1/acceso-a-la-innovacin-en-oncologa monthly 0.5 2024-03-19 https://www.onconius.com/blog-1/los-anticuerpos-conjugados-asociados-a-inmunoterapia-llegan-a-la-primera-lnea-de-tratamiento-en-cncer-de-vejiga-avanzado monthly 0.5 2024-03-08 https://www.onconius.com/blog-1/5sttgd5fj2ja1ol389g1t435dr2h8z monthly 0.5 2023-12-27 https://www.onconius.com/blog-1/inhibidores-de-parp-iparp-nuevos-frmacos-en-el-cncer-de-prstata-resistente-a-la-castracin-metastsico-cprcm monthly 0.5 2023-08-19 https://www.onconius.com/blog-1/vorasidenib-un-nuevo-frmaco-para-los-gliomas-de-bajo-grado-idh-mutados-ensayo-indigo monthly 0.5 2023-07-25 https://www.onconius.com/blog-1/ensayo-checkmate-901-la-quimioinmunoterapia-demuestra-beneficio-en-supervivencia-global-en-cncer-de-vejiga-avanzado-en-primera-lnea monthly 0.5 2023-07-25 https://www.onconius.com/blog-1/ensayo-nadim-ii-nivolumab-y-quimioterapia-en-el-escenario-perioperatorio-del-cncer-de-pulmn-no-microctico-estadio-iii monthly 0.5 2023-07-12 https://www.onconius.com/blog-1/estudios-keynote-671-y-neotorch-tratamiento-perioperatorio-en-cncer-de-pulmn-no-microctico monthly 0.5 2023-06-28 https://www.onconius.com/blog-1/ensayo-contact-03-en-cncer-renal-avanzado-cuando-ms-no-es-mejor monthly 0.5 2023-06-12 https://www.onconius.com/blog-1/estudio-adaura-osimertinib-adyuvante-en-cncer-de-pulmn-no-microctico-con-egfr-mutado monthly 0.5 2023-06-08 https://www.onconius.com/blog-1/qev1znv5as9acxwlrghr9d0njxybdg monthly 0.5 2023-06-02 https://www.onconius.com/blog daily 0.75 2025-01-29 https://www.onconius.com/blog/comunicacin-mdico-paciente-clave-para-una-atencin-de-calidad monthly 0.5 2025-02-02 https://www.onconius.com/blog/controversias-en-cncer-renal monthly 0.5 2025-01-29 https://www.onconius.com/blog/la-importancia-del-ejercicio-fsico-en-el-paciente-oncolgico monthly 0.5 2024-07-20 https://www.onconius.com/blog/nivolumab-adyuvante-mejora-la-supervivencia-global-en-pacientes-con-cncer-de-vejiga-resultados-del-estudio-checkmate-274 monthly 0.5 2024-04-06 https://www.onconius.com/blog/acceso-a-la-innovacin-en-oncologa monthly 0.5 2024-03-19 https://www.onconius.com/blog/los-anticuerpos-conjugados-asociados-a-inmunoterapia-llegan-a-la-primera-lnea-de-tratamiento-en-cncer-de-vejiga-avanzado monthly 0.5 2024-03-08 https://www.onconius.com/blog/amivantamab-y-lazertinib-2-nuevos-actores-en-cncer-de-pulmn-en-primera-lnea monthly 0.5 2023-12-27 https://www.onconius.com/blog/inhibidores-de-parp-iparp-nuevos-frmacos-en-el-cncer-de-prstata-resistente-a-la-castracin-metastsico-cprcm monthly 0.5 2023-08-19 https://www.onconius.com/blog/vorasidenib-un-nuevo-frmaco-para-los-gliomas-de-bajo-grado-idh-mutados monthly 0.5 2023-07-25 https://www.onconius.com/blog/ensayo-checkmate-901-la-quimioinmunoterapia-demuestra-beneficio-en-supervivencia-global-en-cncer-de-vejiga-avanzado-en-primera-lnea monthly 0.5 2023-07-25 https://www.onconius.com/blog/ensayo-nadim-ii-nivolumab-y-quimioterapia-en-el-escenario-perioperatorio-del-cncer-de-pulmn-no-microctico-estadio-iii monthly 0.5 2023-07-12 https://www.onconius.com/blog/estudios-keynote-671-y-neotorch-tratamiento-perioperatorio-en-cncer-de-pulmn-no-microctico monthly 0.5 2023-06-28 https://www.onconius.com/blog/ensayo-contact-03-en-cncer-renal-avanzado-cuando-ms-no-es-mejor monthly 0.5 2023-06-12 https://www.onconius.com/blog/estudio-adaura-osimertinib-adyuvante-en-cncer-de-pulmn-no-microctico-con-egfr-mutado-3ka9l monthly 0.5 2023-06-12 https://www.onconius.com/blog/qu-es-onconius monthly 0.5 2023-06-06 https://www.onconius.com/about daily 0.75 2023-07-12 https://images.squarespace-cdn.com/content/v1/6411b07aaa32e618655cc0ee/a920c877-714b-49f3-b3b3-4b1b551b1bb0/IMG_7336.jpg https://www.onconius.com/contact daily 0.75 2023-06-08